98%
921
2 minutes
20
The three most common kinds of urologic malignancies are prostate, bladder, and kidney cancer, which typically cause substantial morbidity and mortality. Early detection and effective treatment are essential due to their high fatality rates. As a result, there is an urgent need for innovative research to improve the clinical management of patients with urologic cancers. A type of small noncoding RNAs of 22 nucleotides, microRNAs (miRNAs) are well-known for their important roles in a variety of developmental processes. Among these, microRNA-21 (miR-21) stands out as a commonly studied miRNA with implications in tumorigenesis and cancer development, particularly in urological tumors. Recent research has shed light on the dysregulation of miR-21 in urological tumors, offering insights into its potential as a prognostic, diagnostic, and therapeutic tool. This review delves into the pathogenesis of miR-21 in prostate, bladder, and renal cancers, its utility as a cancer biomarker, and the therapeutic possibilities of targeting miR-21.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11304453 | PMC |
http://dx.doi.org/10.3389/fcell.2024.1437951 | DOI Listing |
JCO Clin Cancer Inform
September 2025
USC Institute of Urology and Catherine and Joseph Aresty Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA.
Purpose: To evaluate a generative artificial intelligence (GAI) framework for creating readable lay abstracts and summaries (LASs) of urologic oncology research, while maintaining accuracy, completeness, and clarity, for the purpose of assessing their comprehension and perception among patients and caregivers.
Methods: Forty original abstracts (OAs) on prostate, bladder, kidney, and testis cancers from leading journals were selected. LASs were generated using a free GAI tool, with three versions per abstract for consistency.
World J Urol
September 2025
Uro-Oncology Program, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Purpose: We aimed to evaluate the impact of day- and night-time pad wetness on 2yrs-QoL after Radical Cystectomy (RC) with Orthotopic Neobladder (ON) from a Randomized Controlled Trial (RCT) aimed at comparing open RC (ORC) and Robot-Assisted RC (RARC) with intracorporeal (i) ON.
Methods: Between January 2018 and September 2020, 116 patients were enrolled. Data from self-assessed questionnaires (EORTC-QLQ-C30 and QLQ-BLM30) were collected.
Elife
September 2025
Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Immunogenic cell death (ICD) is a type of cell death sparking adaptive immune responses that can reshape the tumor microenvironment. Exploring key ICD-related genes in bladder cancer (BLCA) could enhance personalized treatment. The Cancer Genome Atlas (TCGA) BLCA patients were divided into two ICD subtypes: ICD-high and ICD-low.
View Article and Find Full Text PDFCancer Med
September 2025
Institute for Regenerative Medicine, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
Background: Patients with clear cell renal cell carcinoma (ccRCC) often undergo organ resection, with treatment strategies based on recurrence risk. Current metastatic potential assessments rely on the WHO/ISUP grading system, which is subject to interobserver variability.
Methods: We developed an artificial intelligence (AI) model to classify cells according to contemporary grading rules and evaluated the prognostic significance of tumor cell profiles, particularly focusing on cells with prominent nucleoli.
World J Urol
September 2025
Department of Urology and Transplantation Surgery, Nantes University Hospital, Nantes, France.
Purpose: In 5-10% of cases, renal cancer extends into the venous system, particularly the inferior vena cava (IVC), which worsens prognosis. This study aims to assess morbidity, mortality, and oncological outcomes of patients treated surgically for renal cancer with IVC extension over a 30-year period, in two experienced centers.
Materials And Methods: This bicentric, retrospective study analyzed patients treated between 1988 and 2020 for renal cancer involving the IVC.